FindTrial
Sign In

pharmacoeconomic evaluation of antidiabetic drugs

pharmacoeconomic evaluation: cost effectiveness analysis of oral antidiabetic drugs in type 2 diabetes patients in a tertiary care hospital - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/055043
Enrollment
115
Registered
2023-07-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications Health Condition 2: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: NIL: NIL

Sponsors

Deeksha M
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients of age 18 years and above of both genders. patients who have be admitted to general medicine and OPD with type 2 diabetes mellitus.

Exclusion criteria

Exclusion criteria: patients with pregnant and lactating women, patients on insulin therapy, patients with type 1 diabetes, patients with cognitive impairment and patients in ICU.

Design outcomes

Primary

MeasureTime frame
The study results will give an overview of cost effectiveness of oral antidiabetic drugs on type 2 diabetics patients which helps in selecting effective drug & also improves patients outcome by selecting proper drug therapy & also determines the minimum & maximum percentage price variation for different classes of oral antidiabetic drugsTimepoint: 015 30DAYS—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactGrinton Josvi Veigas

Karavali College of Pharmacy

grin2veigas@gmail.com9901751579

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026